Tokyo, Dec. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059774) titled 'Utilization and cost estimation in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) in Japan - A National Database Study' on Dec. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Nippon Boehringer Ingelheim Co., Ltd
Condition:
Condition - IPF, PPF, and non-progressive ILD
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To describe the treatment patterns of antifibrotic drugs in patients with IPF and PPF in Japan
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who received first administration of antifibrotic drugs after August 31, 2015
Patients diagnosed with fibrosing ILD on or before the month of the index date
Patients aged 20 years or older on the index date
Having record at least 30 days from the date of first administration of antifibrotic drugs
Patients having record at least 12 months prior to the index date
Key exclusion criteria - Patients who have lung transplantation before the index date
Target Size - 160000
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 09 Month 05 Day
Date of IRB - 2025 Year 10 Month 02 Day
Anticipated trial start date - 2026 Year 04 Month 01 Day
Last follow-up date - 2026 Year 06 Month 01 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068326
Disclaimer: Curated by HT Syndication.
